TOPLINE:

Among adults with a diagnosis of psoriatic arthritis (PsA), those on combination targeted therapy did not have a significantly increased risk for serious bacterial infection or opportunistic infection compared with those on standard therapy.

METHODOLOGY:

Researchers used IBM MarketScan data from 2015 to 2024 to identify adult patients with PsA, focusing on those who received combination targeted therapy and the risk for infections in these patients.

Patients on combination targeted therapy were those with 3, 4, or 6 consecutive months of overlapping medication data for two or more biologics or targeted synthetic disease-modifying antirheumatic drugs. The standard therapy cohort included patients with similar medication data for any PsA-related drug classes.

Among 82,399 patie

See Full Page